- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01579058
Effect of Bisoprolol on Progression of Aortic Stenosis (BLAST)
A Randomized Trial of Beta-blocker Therapy in Aortic Stenosis
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Aortic stenosis (AS) is a gradually progressive disease, characterized by an increase in calcium deposition leading to progressive narrowing of the aortic valve (AV). There are currently no effective medical treatment to halt the disease process and surgical valve replacement remains the only proven therapy when the valve becomes severely stenotic. AS is mediated by a chronic inflammatory disease process, very similar to that seen in atherosclerosis, but lipid-lowering therapy did not slow the progression of AS in the SALTIRE, SEAS, or ASTRONOMER trials. It is possible that these trials may have targeted patients in whom disease was too advanced for lipid-lowering therapy to be effective, or in whom atherosclerotic mechanism was not the central pathogenic process in AS. Because identifying and treating patients in earlier stages of AS would not be cost-effective, it seems more logical to explore alternative pharmacological approaches.
AS has been thought to be a degenerative process basically induced by long-lasting mechanical stress, and hemodynamic factors such as shear forces, acceleration of blood flow, hypertension and rapid heart rate might contribute to progression of AS. Peak aortic jet velocity is known to be associated with clinical outcomes in mild and moderate AS, and our previous study showed that rate of progression was significantly associated with baseline aortic jet velocity in mild AS. Because beta-blocker therapy would decrease aortic jet velocity and heart rate, it might decrease hemodynamic stress and eventually slow down the degenerative process in patients whose disease is not too advanced for therapy to be effective. In a retrospective, observational study, beta-blocker therapy was associated with a favorable clinical outcome in AS.
The investigators hypothesized that bisoprolol, a new generation beta-blocker, would decrease the rate of progression of AS by modifying hemodynamic factors favorably in patients with mild to moderate AS.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Seoul, Korea, Republic of
- Seoul National University Hospital
-
Seoul, Korea, Republic of, 135-710
- Samsung Medical Center
-
Seoul, Korea, Republic of, 138-736
- Asan Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Mild to moderate aortic stenosis defined by peak velocity of aortic jet between 2.0 and 3.5 m/sec
- Untreated hypertension: systolic BP ≥ 140 or diastolic BP ≥ 90 mmHg Treated hypertension using dihydropiridine calcium channel blockers, ACE inhibitors, ARB or diuretics
- Patients received no beta-blocker therapy for more than 12 months
Exclusion Criteria:
- Symtomatic aortic stenosis: presence of exertional dyspnea, angina or syncope
- Planned cardiac surgery (e.g., CABG, valve repair or replacement, or aneurysmectomy) or planned major non-cardiac surgery within the study period
- Stroke or resuscitated sudden death in the past 6 months
- Evidence of congestive heart failure, or left ventricular ejection fraction < 50%
- Significant renal disease manifested by serum creatinine > 2.0mg/dL
- History of intolerance to beta-blocker
- History of adult asthma manifested by bronchospasm in the past 6 months, or currently taking regular anti-asthmatic medication(s)
- Moderate or severe aortic regurgitation
- Atrial fibrillation
- Female of child-bearing potential who do not use adequate contraception and women who are pregnant or breast-feeding
- A diagnosis of cancer (other than superficial squamous or basal cell skin cancer) in the past 3 years or current treatment for the active cancer
- Any clinically significant abnormality identified at the screening visit, physical examination, laboratory tests, or electrocardiogram which, in the judgment of the Investigator, would preclude safe completion of the study
- Unwillingness or inability to comply with the procedures described in this protocol
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: placebo
|
placebo for 4 years
|
Active Comparator: bisoprolol
bisoprolol 5mg qd
|
bisoprolol 5mg qd for 4 years
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in peak aortic jet velocity from baseline to 4 years follow-up
Time Frame: 4 years
|
Change in peak aortic jet velocity from baseline to 4 years follow-up.
For each patient, the change in peak aortic jet velocity is calculated as (peak aortic jet velocity at 4 year follow-up) - (peak aortic jet velocity at baseline) on Doppler echocardiography.
|
4 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in mean pressure gradient across aortic valve
Time Frame: 4 years
|
Change in mean pressure gradient across aortic valve from baseline to 4 years follow-up
|
4 years
|
Change in aortic valve area
Time Frame: 4 years
|
Change in aortic valve area from baseline to 4 years follow-up
|
4 years
|
Change in BNP levels
Time Frame: 4 years
|
Change in BNP levels from baseline to 4 years follow-up
|
4 years
|
Change in E/E' ratio
Time Frame: 4 years
|
Change in the ratio of E velocity (early mitral inflow velocity) to E' velocity (early mitral annular velocity) from baseline to 4 years follow-up
|
4 years
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Heart Diseases
- Cardiovascular Diseases
- Pathological Conditions, Anatomical
- Aortic Valve Disease
- Heart Valve Diseases
- Ventricular Outflow Obstruction
- Aortic Valve Stenosis
- Constriction, Pathologic
- Physiological Effects of Drugs
- Adrenergic beta-Antagonists
- Adrenergic Antagonists
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Antihypertensive Agents
- Autonomic Agents
- Peripheral Nervous System Agents
- Sympatholytics
- Adrenergic beta-1 Receptor Antagonists
- Bisoprolol
Other Study ID Numbers
- 2011-0884 (Other Identifier: M D Anderson Cancer Center)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Aortic Stenosis
-
Hospices Civils de LyonRecruiting
-
Abbott Medical DevicesActive, not recruitingSevere Aortic Stenosis | Symptomatic Degenerative Aortic StenosisSpain, Italy, United Kingdom, Germany, Switzerland, Czechia, Australia, Belgium, Poland
-
Edwards LifesciencesActive, not recruitingAortic Stenosis | Aortic Regurgitation | Symptomatic Aortic StenosisChina
-
Anteris Technologies Ltd.Active, not recruitingAortic Valve Calcification | Severe Aortic Valve Stenosis | Symptomatic Aortic StenosisGeorgia
-
Anteris Technologies Ltd.Active, not recruitingAortic Stenosis | Aortic Valve Calcification | Severe Aortic Valve Stenosis | Symptomatic Aortic StenosisUnited States
-
Edwards LifesciencesCompletedAortic Stenosis | Aortic Regurgitation | Symptomatic Aortic StenosisChina
-
Ningbo Jenscare Biotechnology Co., Ltd.UnknownAortic Regurgitation | Severe Aortic Stenosis
-
Genesis Medtech CorporationRecruitingDiseases of Aortic Valve | Aortic Stenosis DiseaseChina
-
Pan XiangbinRecruiting
-
Colibri Heart Valve LLCRecruiting
Clinical Trials on bisoprolol
-
Merck KGaA, Darmstadt, GermanyMerck Ltd.Completed
-
Merck KGaA, Darmstadt, GermanyMerck Gesellschaft mbH, AustriaCompleted
-
Merck KGaA, Darmstadt, GermanyCompletedHypertensionGermany
-
Université de SherbrookeLaval UniversityCompleted
-
State Institution "Republican Scientific and Practical...CompletedWomen With Breast CancerBelarus
-
Merck KGaA, Darmstadt, GermanyMerck Inc., PhilippinesCompleted
-
Peking Union Medical College HospitalNational Natural Science Foundation of China; Cancer Institute and Hospital...Recruiting
-
Damanhour UniversityAlexandria UniversityCompletedAcute Coronary SyndromeEgypt
-
Damanhour UniversityAlexandria UniversityCompletedAcute Coronary SyndromeEgypt
-
University Hospital, CaenUnknownHeart Failure With Reduced Ejection FractionFrance